Methyl hydrazinecarbimidothioate hydroiodide
CAS: 35600-34-1
Ref. 3D-FM133227
| 1g | Discontinued | ||
| 2g | Discontinued | ||
| 5g | Discontinued | ||
| 10g | Discontinued | ||
| 25g | Discontinued |
Product Information
Name:
Methyl hydrazinecarbimidothioate hydroiodide
Synonyms:
- Hydrazinecarboximidothioic acid methyl ester hydroiodide
- Carbamohydrazonothioic Acid, Methyl Ester
- Methyl carbamohydrazonothioate
Description:
Methyl hydrazinecarbimidothioate hydroiodide (MHCDI) is an anti-cancer drug that belongs to the group of alkylating agents. It is a prodrug that must be activated by intramolecular hydrogen chloride to form methyl hydrazine, which reacts with the DNA nucleotide bases. MHCDI is used in clinical studies for the treatment of pancreatic cancer, colorectal cancer, and other cancers. MHCDI is administered intravenously, orally, or intraperitoneally. MHCDI binds to nitrogen atoms in the vasoactive intestinal peptide and reacts with hydrochloric acid to form a pyrazole ring. The reaction products are then excreted from the body.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:
Chemical properties
Molecular weight:
233.08 g/mol
Formula:
C2H8IN3S
Purity:
Min. 95%
Color/Form:
White Powder
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
